Product logins

Find logins to all Clarivate products below.


Parkinson’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Parkinson’s Disease (US)

Parkinson’s disease (PD) is a progressive neurodegenerative condition that is treated chronically with prescription therapies from an array of mechanistically distinct drug classes, including dopamine precursors, dopamine agonists, and MAO-B inhibitors. Individualized care, a high level of polypharmacy, and frequent adjustments as patients progress through lines of therapy are all required for PD treatment. A growing number of branded agents targeting niche subpopulations with high unmet need (e.g., Inbrija [Acorda], Gocovri [Supernus], Nourianz [Kyowa Kirin]) have entered a market dominated by entrenched, generic standards of care. With the market poised to further expand as a result of a pipeline of unique therapies offering potential clinical improvements (e.g., AbbVie’s Vyalev, Amneal’s IPX-203), understanding the treatment dynamics in competitive segments of the PD therapy market will be crucial for drug developers and marketers of in-line products.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PD patients?
  • How has Inbrija been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of PD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: AbbVie, Acadia, Acorda, Amneal, Kyowa Kirin, Lundbeck, Neurocrine, Sunovion, Supernus

Key drugs: Duopa, Gocovri, Inbrija, Neupro, Northera, Nourianz, Nuplazid, Ongentys, Rytary, Xadago, all generic mainstays

SOLUTION ENHANCEMENT

The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more-detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
Report
Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…